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Abstract
Introduction: Thalassemia screening program has been implemented for years in Southeast Asia, but no external quality assessment program has 
been established. We have developed and initiated the proficiency testing (PT) program for the first time in Thailand with the aim to assess the scre-
ening performance of laboratory staff and their competency in interpretation of the screening results.
Materials and methods: Three PT cycles per year were organized. From the first to the third cycle of the PT scheme, a total number of participant 
laboratories increased from 59 to 67. In each cycle, 2 PT items (assigned as blood samples of the couple) were provided. Performance evaluation was 
based on the accuracy of screening results, i.e. mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH) and the dichlorophenolin-
dophenol (DCIP) test for haemoglobin E, including the competency in interpretation of screening results and assessment of foetal risk. Performance 
was assessed by comparing the participants’ result against the assigned value.   
Results: Of all 3 cycles, most laboratories reported acceptable MCV and MCH values. From the first to the third cycle, incorrect DCIP test and misin-
terpretation rates were decreased while incorrect risk assessment varied by cycle to cycle. Combining the accuracy of thalassemia screening and the 
competency in interpretation and risk assessment, approximately half of participants showed excellent performance.  
Conclusion: Improved performance observed in many laboratories reflects the achievement and benefit of the PT program which should be regu-
larly provided.
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Amongst the inherited blood disorders in South-
east Asia, thalassemia is the most common one. It 
is also considered as an emerging burden of health 
among the world population (1,2). In this region, 
although there are several forms of thalassemia, 
only three severe forms namely haemoglobin (Hb) 
Bart’s hydrops fetalis (homozygous α0-thalas-
semia), homozygous β-thalassemia and Hb E-β-
thalassemia are of major concern, requiring appro-
priate prevention and control program (3). As such, 
a prevention and control program has long been 
implemented. The ultimate goal of the program is 
to reduce the incidence of these three severe dis-
eases. The program comprises three steps: 1) 
screening for thalassemia in pregnant women and 
their husbands, 2) providing genetic counselling 
to the at-risk couples, and 3) offering after genetic 
counselling, option for a prenatal diagnosis and ter-
mination of pregnancy with affected foetus (3,4). 
In Thailand, screening for thalassemia is obligatory 
and financed by the National Health Security Of-
fice. The national policy demands all primary 
health care facilities providing thalassemia screen-
ing to all pregnant women and their husbands at 
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the first visits. Screening procedures include the 
measurement of mean corpuscular volume (MCV) 
and/or mean corpuscular haemoglobin (MCH) to 
identify suspected carriers of α0-thalassemia and 
β-thalassemia, and the dichlorophenolindophenol 
(DCIP) test for Hb E (5,6). Based on this screening 
strategy, blood samples of positive cases are sent 
to referral centres to investigate further with Hb 
and DNA analyses for definite diagnosis. For those 
with negative results, no further investigation is 
required. Therefore, it is crucial that initial screen-
ing must be accurate. Due to the lack of proficien-
cy testing scheme, information on the perfor-
mance of initial thalassemia screening of laborato-
ries in the country is not available so far.         
In this study, we have developed and initiated the 
proficiency testing (PT) program for the first time 
in Thailand aiming to assess the screening perfor-
mance of laboratory staff and their competency in 
interpretation of the screening results. Because of 
the complexity of thalassemia in the country, we 
hypothesized that there might be incorrect inter-
pretation and/or risk assessment among laborato-
ry staff. Information obtained from the study would 
inspire health authorities of all similar settings to es-
tablish the PT program within the region.     
Materials and methods
Preparation of PT items for thalassemia 
screening and the participants
Ethical approval of the study protocol was ob-
tained from the Ethical Committee of Khon Kaen 
University, Thailand (HE582243). Appropriate hu-
man blood samples were selectively collected and 
used in preparation of the PT items. After in-
formed-consent was obtained, 15 - 20 mL periph-
eral blood samples anticoagulated with acid cit-
rate dextrose (ACD) were collected from two do-
nors, i.e. normal individual (normal Hb-type with 
normal MCV and MCH) and Hb E carrier. Only one 
sample from each donor was taken. Baseline val-
ues of MCV and MCH were measured using Sys-
mex XS-800i haematology analyser (Sysmex, Kobe, 
Japan) and Coulter Hematology Analyzers (COUL-
TER® LH780 Hematology Analyzer, Beckman Coul-
ter, USA). Then, blood samples were preserved with 
the phosphate–adenine–glucose–guanosine–sa-
line–mannitol (PAGGSM) reagent as described pre-
viously (7). In brief, one volume of PAGGSM was 
added into 3.5 volumes of blood sample and mix-
tures were mixed continuously on a rotating mixer 
at 400 x g for 60 minutes. After storing at 2-6 0C for 
48 hours for stabilization of red blood cell (RBC) pa-
rameters, aliquots of the mixtures were distributed 
on ice to the participants for analysis within 1 week. 
Prior to distribution, two aliquots of each PT item 
were randomly selected to perform MCV and MCH 
measurement and DCIP test. Homogeneity and 
stability of the PT items prepared were tested ac-
cording to the ISO/IEC 17043 (8). General character-
istics of the PT items prepared were summarized in 
Tables 1 and 2. To minimize variation in the types 
of haematology analysers used (9), members of the 
two manufacturers, i.e. the Sysmex Co., Ltd. and the 
Beckman Coulter Co., Ltd., were invited. These two 
companies agreed with the PT program. The repre-
sentatives of each company were responsible for 
invitation and transportation of PT items on time to 
the invited participants. 
The proficiency testing scheme
Three cycles of the PT program were applied dur-
ing June 2015 to May 2016. From the first to the 
third cycle of the PT scheme, numbers of partici-
pant laboratories were 30, 26 and 27 for group of 
participants using Sysmex Hematology Analyzer 
series, in cycles 1, 2, and 3, respectively. In contrast, 
number of those participants using Beckman 
Coulter Analyzer series increased from 29 in cycle 
1, to 39 in cycle 2, and to 40 in cycle 3. Participants 
were asked to measure MCV and MCH values and 
perform the DCIP test within 24 hours of receiving 
the PT items. In brief, laboratory staff was asked to 
add 0.02 ml of each blood sample into 2 ml of DCIP 
reagent, and incubate the mixture at 37 0C for 15 
minutes. After stopping the reaction by adding 
0.02 ml of the stop-solution, laboratory staff re-
ported the DCIP screening results according to the 
turbidity observed by naked-eye.   
In each cycle, 2 PT items were prepared and as-
signed as blood samples of pregnant woman, and 
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Characteristics
Cycle 1 Cycle 2 Cycle 3
QCM-1A QCM-1B QCM-2A QCM-2B QCM-3A QCM-3B





MCV (fL)* 91.1 ± 1.5 78.1 ± 0.9 69.0 ± 0.5 73.1 ± 0.3 65.7± 0.3 64.1± 0.5
MCH (pg)* 29.3 ± 0.2 25.1 ± 0.2 21.7 ± 0.4 23.6 ± 0.2 21.3 ± 1.0 20.5 ± 0.2
DCIP Test Negative Positive Negative Positive Positive Positive
Summary of the 







Suspected Hb E 
with or without 





Suspected Hb E 
with or without 
α- thal and/or 
β-thal
Suspected 
Hb E with or 
without α-thal 
and/or β-thal
Suspected Hb E 
with or without 
α- thal and/or 
β-thal
Fetal risk ‡ No risk
Homozygous α0-thalassemia
Homozygous β-thalassemia
β-thalassemia / Hb E
Homozygous α0-thalassemia
Homozygous β-thalassemia
β-thalassemia / Hb E
*Measured using COULTER® LH780 (Beckman Coulter, USA).
Either MCV/DCIP or MCH/DCIP; MCV< 80 fL or MCH < 27 pg was considered positive (- / -; negative for both test, + / -; positive for 
MCV (or MCH) but negative DCIP, - / +; negative MCV (or MCH) but positive DCIP, + / +; positive for both tests).
‡Based on screening results of pregnant woman and her husband; diseases at risk being assessed were homozygous α0-thalassemia, 
homozygous β-thalassemia and β-thalassemia / Hb E.
PT - proficiency testing; MCV - mean corpuscular volume; MCH - mean corpuscular haemoglobin; DCIP – dichlorophenolindophenol.
Table 1. Characteristics of the PT items provided for participants using Coulter hematology analyzer
Characteristics
Cycle 1 Cycle 2 Cycle 3
QCM-1A QCM-1B QCM-2A QCM-2B QCM-3A QCM-3B
Assigned code Husband Pregnant woman Husband
Pregnant 
woman Husband Pregnant woman
MCV (fL)* 85.2 ± 2.2 61.3 ± 1.1 63.7 ± 0.5 74.9 ± 0.8 58.8 ± 1.6 89.1 ± 0.7
MCH (pg)* 27.9 ± 0.3 19.8 ± 0.1 20.1 ± 0.2 24.5 ± 0.7 21.0 ± 0.1 27.8 ± 0.2
DCIP Test Negative Positive Negative Positive Positive Negative
Summary of the 






Suspected Hb E 
with or without 






Hb E with or 
without α-thal 
and/or β-thal
Suspected Hb E 
with or without 





Fetal risk‡ No risk
Homozygous α0-thalassemia 
Homozygous β-thalassemia 
β-thalassemia / Hb E
No risk
*Measured using Sysmex XS-800i (Sysmex, Kobe, Japan). 
†Either MCV/DCIP or MCH/DCIP; MCV < 80 fL or MCH < 27 pg was considered positive (- / -; negative for both test, + / -; positive for 
MCV (or MCH) but negative DCIP, - / +; negative MCV (or MCH) but positive DCIP, + / +; positive for both tests).
‡Based on screening results of pregnant woman and her husband; diseases at risk being assessed were homozygous α0-thalassemia, 
homozygous β-thalassemia and β-thalassemia / Hb E. 
PT - proficiency testing; MCV - mean corpuscular volume; MCH - mean corpuscular hemoglobin; DCIP – dichlorophenolindophenol.
Table 2. Characteristics of the PT items provided for participants using the Sysmex haematology analyser.
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her husband. Along with the PT items, detail in-
structions, necessary information and report form 
were provided for participants. The performance 
assessment comprised 3 parts; Part I: Accuracy of 
MCV & MCH measurements and DCIP testing, Part 
II: Competency in interpretation of the screening 
results, and Part III: Competency in assessing the 
risk of foetus of having the three severe thalassem-
ia diseases (Table 3).  
Evaluation criteria
Different evaluation criteria were applied, as de-
scribed below.
Accuracy of initial screening test
To minimize variation associated with different 
haematology analysers, performance of MCV and 
MCH measurements was evaluated separately for 
the 2 groups of participants (9). Accuracy of MCV 
and MCH measurements were evaluated against 
the assigned values obtained from the consensus 
values of each participant group. Assigned values 
were calculated using robust statistical methods 
as recommended by the ISO 13528 (10). A z-score 
was calculated directly from the result reported by 
the participant in relation to an acceptable varia-
tion of all results to the assigned value [(partici-
pant result - assigned value) / standard deviation] 
for proficiency assessment. A z-score within - 2 to 
2 was considered acceptable. A bar-chart of z-
score was constructed to demonstrate perfor-
mance of all participants. For qualitative DCIP test 
for Hb E, the result of each participant (either posi-
tive or negative) was compared directly with the 
assigned value defined by Hb analysis using capil-
lary electrophoresis system (Capillarys II Flex Piec-
ing, Sebia corp., France) at our laboratory (11). Pro-
portions of participants reporting incorrect result 
were calculated and compared between cycles, i.e. 
cycles 1 and 2, cycles 1 and 3, and cycles 2 and 3. 
Competency in interpretation of thalassemia 
screening 
Interpretation of competency was evaluated ac-
cording to standard screening guidelines, using 
MCV and/or MCH in combination with DCIP test 
(5,6). There are 4 categories of the screening re-
sults and interpretations; i.e. category A (MCV > 80 
fL or MCH > 27 pg with negative DCIP or (-/-) vari-
ety): non-thalassemia or non-clinically significant 
thalassemia; category B (MCV < 80 fL or MCH < 27 
pg with negative DCIP or (+/-) variety): suspected 
Part I:  Screening result (please check  in the  as appropriate).
QCM No. 1 (PW) MCV/MCH result  Positive   Negative
DCIP-test result  Positive   Negative
QCM No. 2 (Husband) MCV/MCH result  Positive   Negative
DCIP-test result  Positive   Negative
Part II:  Interpretation of screening results (please check  in the  as appropriate) .
•	 QCM No. 1 (PW)                       A   B   C   D
•	 QCM No. 2 (Husband)            A   B   C   D
where   A: Non-thalassemia or non-clinically significant thalassemia
               B: Suspected α-thalassemia and/or β-thalassemia
               C: Suspected Hb E trait
               D: Suspected Hb E with or without α- and/or β-thalassemia 
Part III: Fetal risk assessment (please check  in the  as appropriate. (If relevant, more than 1 category can be selected) .
Disease at risk of the fetus:      A   B   C   D
 where   A:    Hb Bart’s hydrops fetalis
                B:    Homozygous β-thalassemia
                C:    Hb E-β-thalassemia disease
                D:    No risk for the 3 diseases mentioned above
PW – pregnant woman.
Table 3. Report form for the participants
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α0-thalassemia and/or β-thalassemia; category C 
(MCV > 80 fL or MCH > 27 pg with positive DCIP or 
(-/+) variety): suspected Hb E trait; category D 
(MCV < 80 fL or MCH < 27 pg with positive DCIP or 
(+/+) variety): suspected Hb E with or without α- 
and/or β-thalassemia. These 4 categories were 
provided in the report form of the participants, al-
lowing them to select an appropriate category 
based on the screening result of each PT item.  
Competency in risk assessment of the foetus
Each participant was asked to assess the disease 
at-risk of the foetus by combining screening re-
sults obtained from the 2 PT items (which were as-
signed respectively as pregnant woman and her 
husband). The at-risk diseases being assessed in-
cluded A: Hb Bart’s hydrops fetalis (homozygous 
α0-thalassemia); B: homozygous β-thalassemia; C: 
Hb E-β-thalassemia and D: No risk for the three se-
vere thalassemia diseases. Possible patterns of 
screening results of the couples and diseases at 
risk of the foetuses are listed (Table 4). 
As for DCIP test, the proportions of participants re-
porting incorrect results (incorrect interpretation 
of thalassemia screening as well as incorrect risk 
assessment) were calculated and compared be-
tween cycles. 
Performance levels of the participants
The overall performance of each participant was 
defined according to the above three evaluation 
criteria; accuracy of screening tests (MCV, MCH 
and DCIP), competency in interpretation of screen-
ing results and competency in risk assessment of 
the fetus. Four levels of performance are given in 
Table 5.
Statistical analysis
Outcome variables being evaluated included ‘z-
score’ of MCV and MCH, DCIP result, interpretation 
of screening test, risk assessment, and perfor-
mance level. All data obtained from participants 
were entered into Excel spreadsheets. For quanti-
tative test (MCV and MCH measurements), the ro-
bust statistical analysis (Algorithm A; ISO 13528) 
was applied to identify outliers (10). These analy-
ses were performed with the Excel 2013. For quali-
tative tests, proportions of participants reporting 
incorrect results (incorrect interpretation of thalas-
semia screening as well as incorrect risk assess-
Screening result (MCV or 
MCH / DCIP)*
Disease at-risk of the foetus†










Hb Bart’s hydrops fetalis
Homozygous β-thalassemia
Hb E-β-thalassemia disease
- / + Hb E-β-thalassemia disease
+ / -
+ / - Hb Bart’s hydrops fetalisHomozygous β-thalassemia
- / + Hb E-β-thalassemia disease
- / +
- / + No risk for the 3 diseases
- / - No risk for the 3 diseases
*(+ and –) before the slash (/) indicate positive for MCV or 
MCH (either MCV < 80 fL or MCH < 27 pg) and negative (MCV 
> 80 fL or MCH > 27 pg), respectively. (+ and -) after the slash 
(/) indicates the result of dichlorophenolindophenol (DCIP) 
screening test. †Consider for the three target thalassemia 
diseases only.
Table 4. Possible diseases at-risk of the foetus based on the 
screening results of the couple
Level Description
Excellent: Acceptable MCV & MCH values and 
correct DCIP test, correct interpretation of 
thalassemia screening and risk assessment 
of the foetal.
Good: Acceptable MCV & MCH values and 
correct DCIP test, correct interpretation of 
thalassemia screening, but incorrect risk 
assessment of the foetus.
Fair: Acceptable MCV & MCH values and correct 
DCIP test, but incorrect interpretation of 
thalassemia screening and risk assessment 
of the foetus.
Poor: Incorrect result of MCV or MCH or DCIP. No 
further evaluation is performed.
MCV - mean corpuscular volume; MCH - mean corpuscular 
hemoglobin; DCIP - dichlorophenolindophenol.
Table 5. Evaluation of performance levels of the participants
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ment) were calculated and compared between cy-
cles using z-test. Statistical comparison was per-
formed using the Minitab Statistical Software ver-
sion 12.2 (Minitab Inc, Pennsylvania, USA). A P-val-
ue < 0.05 was considered significant.
Results
Accuracy of MCV & MCH measurements and DCIP test
Bar charts of z-scores of participants are illustrated 
in Figure 1 (for Beckman Coulter Analyzers) and 
Figure 2 (for Sysmex Haematology Analysers). The 
majority of participants in both groups could re-
port acceptable MCV and MCH values, as indicated 
by z < ± 2.  For DCIP test, the proportion of labora-
tories reporting incorrect result was 6/59 in the first 
cycle, 4/65 in the second cycle, and 1/67 in the third 
cycle of the PT scheme (Table 6). There was no sta-
tistically significant difference between cycles.
Competency in interpretation and assessing the risk 
of foetus
Incorrect interpretation of screening results and 
risk assessment of the foetus are shown in Table 6. 
In the first cycle, 20 out of 59 participants inter-
preted screening results incorrectly. The propor-
tion of incorrect interpretation decreased to 16/65 
in second cycle, and to 14/67 in third cycle. How-
ever, no statistically significant difference between 
cycles was obtained.
The competency in assessing the risk of foetus 
based on screening test results showed fluctua-
tion. A high proportion of incorrect risk assess-
ment was observed in second cycle (37/65) 
whereas in cycles 1 and 3, the proportions of in-
correct risk assessment (11/59 for cycle 1 and 
13/67 for cycle 3) were significantly lower than 
that of cycle 2. 
Figure 1. Bar charts of z-scores of participants of the Beckman Coulter 
Y- and X- axes represent z-score, and participant number, respectively. Black and grey lines respectively represent z-score of MCV and 
MCH obtained from 2 PT items. Laboratories participating in the first cycle were coded as numbers 1-29. New laboratories partici-
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Assessing item Cycle 1 Cycle 2 Cycle 3
DCIP test 6/59 (10.2) 4/65 (6.2) 1/67 (1.5)
Interpretation of screening results 20/59 (33.9) 16/65 (24.6) 14/67 (20.9)
Risk assessment of the foetus 11/59 (18.6) 37/65 (56.9)* 13/67 (19.4)†
Values are presented as proportions (percentage). *Significantly differs from cycles 1 and 3 (P < 0.001). †Significantly differ from 
















Figure 2. Bar charts of z-scores of participants of the Sysmex 
Y- and X- axes represent z-score, and participant number, respectively. Black and grey lines respectively represent z-score of MCV and 
MCH obtained from 2 PT items. Laboratories participating in the first cycle were coded as numbers 1-30. New laboratories participat-
ing in the second and the third cycles were coded from 31-35. In the second and third cycles, 9 and 8 participants did not submit their 
results (no. 22-30 for cycle 2 and no.3, 8, 19, 20, 29, 30, 33, 34 for cycle 3). 
Table 6. Laboratories reporting incorrect results 
Proficiency levels of participants
Figure 3 illustrates the proficiency levels of partici-
pants in 3 cycles of the PT scheme. Excellent per-
formance was obtained in 28/59 (47.5%) of partici-
pants in cycle 1, 25/65 (38.5%) in cycle 2, and 38/67 
(56.7%) in cycle 3. In contrast, poor performance 
was respectively noted at 14/59 (23.7%), 17/65 
(26.2%) and 14/67 (20.9%) in the cycles 1, 2 and 3. 
Performance of individual participant in each 
round is also illustrated (Figure 4). A few laborato-
ries could maintain their excellent performance for 
all 3 cycles, e.g. participant numbers 1-5 of the first 
group using Beckman Coulter Haematology Ana-
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Figure 4. Graphic summary of performance level of each participant obtained from 3 cycles for A: Beckman Coulter and B: Sysmex 
hematology analyzers. 
Y- and X- axes represent performance level, and participant number, respectively. Symbols used to indicate the four levels are as fol-











Cycle 1 (N = 59) Cycle 2 (N = 65) Cycle 3 (N = 67)












Figure 3. Proficiency levels of participants in 3 cycles of the PT 
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A:  Beckman Coulter Hematology Analyzers
B:  Sysmex Hematology Analyzers
lysers and participant numbers 1-2 of the second 
group with Sysmex Haematology Analysers. How-
ever, it could be seen that many of them improved 
their performance in the second and/or the third 
cycle of the PT scheme.
Discussion
In this study, we report the results of PT program 
for thalassemia screening initiated for the first 
time in our country. It was found that approxi-
mately half of participants had excellent perfor-
mance and most of the non-excellent performanc-
es are due to incorrect interpretation and/or risk 
assessment. Our PT schemes included quantita-
tive, qualitative and interpretive tests. For quanti-
tative test, although most laboratories could re-
port acceptable MCV and MCH values, falsely high 
values were occasionally seen, resulting in unac-
ceptable z-scores of higher than 2 (Figures 1 and 
2). This information is especially important for 
thalassemia screening in that the falsely high val-
ues of MCV & MCH could lead to false negative in 
thalassemia screening. In general, false positive 
might occur at a thalassemia screening as report-
ed previously (5,6,12), but this does not matter 
since major concern would be false negative. It is 
crucial therefore that false negative should be 
kept at minimum since this can result in an inci-
dence of newborn with severe thalassemia syn-
dromes. The evaluation results obtained from the 
PT program are therefore helpful for participants 
to identify and fix such serious problems.
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In addition to MCV and MCH, DCIP test is also nec-
essary for identifying individuals with Hb E 
(5,6,13,14). Although the test is simple and rapid, 
the result is highly observer dependent and ade-
quate practice is required before performing the 
test (15). Results from this PT program showed that 
some participants performed DCIP test incorrectly 
(Table 5). We observed that in comparison to pro-
vincial hospitals, participants from smaller hospi-
tals in the community performed the test with less 
accuracy. In consistent with this finding, we also 
observed a high rate of incorrect DCIP results in re-
ferred samples from community hospital for con-
firmation of thalassemia at our centre. This is not 
unexpected because with limited resources and 
budgets and high routine workload, staffs of these 
community hospitals usually have lower chance of 
training. Nonetheless, without the PT program 
they would not know their performance on thalas-
semia screening. The test is used widely in Thai-
land and currently distributed to the low-middle 
income countries nearby (5,6,12,16). This informa-
tion would therefore make the health staff recog-
nize the limitation of the test.
Competency in interpretation of screening results 
and assessment of foetal risk for severe thalas-
semias are other issues being evaluated. Whether 
laboratory staffs understand the results is crucial 
for communicating with the couple and other al-
lied health personals at the hospitals, especially for 
genetic disease (17). Also, knowing the risk of the 
expecting foetus of the screened couples will cer-
tainly allow them to realize the importance of the 
accurate screening results. Under this PT program, 
it was found that approximately 1/3 of participants 
in the first round interpreted thalassemia screen-
ing incorrectly. Although no statistical significance 
was achieved, it appears that incorrect results de-
creased gradually during the second and for 1/5 in 
the third cycle. This may reflect an improvement in 
the interpreting skill of laboratory staff and sup-
port the benefit of the PT program. 
In contrast to the competency in interpretation of 
screening results, incorrect assessment of foetal 
risk fluctuated from cycle to cycle. It is noteworthy 
that a proportion of incorrect risk assessment was 
particularly high for the second cycle of the PT 
scheme. This can be explained by the fact that in 
the second cycle, more complex cases were sup-
plied. Both PT items were positive for MCV & MCH. 
Only one of them was positive for the DCIP test 
(Tables 3 and 4). Therefore, based on the screening 
results, the husband was suspected carrier of α- or 
β-thalassemia whereas the pregnant woman 
could be carrier of α- or β-thalassemia or Hb E (5). 
Accordingly, the expecting foetus could be at risk 
of having all the 3 thalassemia diseases including 
Hb Bart’s hydrops fetalis, β-thalassemia major and 
Hb E-β-thalassemia. Unfortunately, many partici-
pants reported the risk of having only one or two 
diseases. This reflects in part insufficient knowl-
edge among participants. As for the DCIP test 
mentioned above, most of the misinterpretation 
and incorrect assessment of foetal risk were from 
community hospitals. 
There are several approaches to evaluate the over-
all performance of participants. For thalassemia 
prevention and control program, we believe that 
detection of carriers of severe thalassemia, provid-
ing accurate interpretation of laboratory results 
and risk assessment of the corresponding inherit-
ance and interaction are very important. These 
would require appropriate knowledge of the 
pathophysiology, genetic inheritance, and geno-
type-phenotype interactions of the diseases. As 
for other genetic disorders, it is necessary to have 
accurate laboratory results as well as accurate in-
terpretation and risk assessment (17). In this study, 
we combined the accuracy of screening test and 
the competency in interpretation and risk assess-
ment as the performance criteria. On average, only 
half of participants had excellent performance 
(Figure 3). Taking all evaluated items into account, 
the main reasons explaining the poor perfor-
mance appear to be incorrect interpretation and 
risk assessment of the expecting foetus. Similarly, 
misinterpretations and risk assessments were also 
observed previously in a PT program on Hb analy-
sis (18). Because different cases with different com-
plexity were assigned in each cycle, it is therefore 
not surprising that several laboratories could not 
maintain their excellent performance. Perfor-
mance of some participants even swung up and 
down (Figure 4). Our results indicate that the PT 
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program should be continuously operated in par-
allel with extensive education program on thalas-
semia screening to all laboratories to warrant the 
better understanding and maintain the goal of the 
PT program. 
To our best knowledge, only a few papers con-
cerning PT programs for thalassemia have been 
published. Proficiency testing of hemoglobinopa-
thy techniques in Ontario laboratories initiated in 
1989 focused on the accuracy of screening test for 
sickle cell disease and Hb electrophoresis (19). 
More recent study of external quality assessment 
conducted in Italy focused on Hb A2 measurement 
and genotyping of β-thalassemia (20,21). The 
Dutch Foundation for Quality Assessment in Medi-
cal Laboratories (SKML) currently provides interna-
tional PT program for thalassemia by assessing the 
accuracy of Hb A2 and Hb F as well as diagnostic 
skill of participants (22). In Thailand, the first PT 
program of Hb analysis in prevention and control 
of severe thalassemia has been initiated since 2012 
(18). Yet, the program does not include the assess-
ment of initial screening performance and compe-
tency of laboratory staff in interpretation and risk 
assessment, which is the first step that can affect 
the success of thalassemia prevention.
Our study has some limitations. Firstly, as we used 
human blood for preparing the PT items, we there-
fore could not provide a large batch of samples for 
a larger number of participants; explaining why 
only members of two haematology manufacturers 
were invited and why we could not use the same 
PT items for the 2 groups of participants. Secondly, 
even though PT items were sent to participants 
under appropriate conditions and packaging, they 
were sometimes deteriorated during transporta-
tion, leading to a withdrawal of participants, par-
ticularly for community hospitals. Nevertheless, 
the study provides a model of PT program for 
thalassemia screening and emphasizes a need for 
setting up such a PT scheme to get a better 
achievement of prevention thalassemia in this re-
gion.  
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